§ 04 · Our mission
To usher in
the Post-Resistance
Era.
By delivering safe, structurally disruptive antimicrobials to millions of patients globally.
§ 01
Structurally disruptive
A multi-site mechanism that resistant pathogens cannot route around.
§ 02
Multi-modal
One patented composition acting across antibacterial, antiviral, and angiogenic fronts.
§ 03
Global reach
Safe antimicrobials delivered to millions of patients globally.
§ 04.1 · The target
The resistance
crisis.
Multi-drug-resistant pathogens outpace conventional antibiotics because every single-site drug eventually selects for resistance. We target the WHO list of multi-drug-resistant pathogens with a mechanism that does not give resistance a foothold.
- - No observed resistance in 20+ yrs
- - WHO priority pathogens
- - Two patented assets
- - Three FDA pathways
§ 04.2 · The approach
One engine,
three fronts.
A patented composition of methylglyoxal, expressed across antibacterial, antiviral, and angiogenic fronts. Not a pipeline of unrelated molecules: one structurally disruptive engine, deployed three ways.
§ 01
Antibacterial
Multi-site cell-wall disruption that pathogens cannot route around.
§ 02
Antiviral
Acts against enveloped respiratory viruses at the point of entry.
§ 03
Angiogenic
Promotes angiogenesis and accelerates tissue repair.
§ 04
De-risked
Two patented assets across three expedited FDA pathways.
§ 04.3 · Regeneration
Not only
defense.
Repair.
Independent, peer-reviewed research documents the biological activity of the composition. Medical Grade Manuka, the botanical matrix, carries a continuous history of human use since 1996.
The same constituent is angiogenic: it promotes angiogenesis and accelerates tissue repair, supporting the conditions required for healing, not merely symptom relief.
§ Continue